Safety Concerns Behind WHO Suspension of Hydroxychloroquine Trials in Coronavirus Treatment

Hydroxychloroquine, a drug primarily used for treating antimalarial conditions and sometimes prescribed for arthritis, has garnered significant attention in recent years. The primary reason for this attention is due to its potential antiviral properties, particularly in the treatment of coronavirus.

Hydroxychloroquine functions by targeting the haeme polymerase enzyme, which inhibits further replication of viruses in the human body. Scientific research has also revealed antiviral activity associated with this drug, which can potentially be effective against the coronavirus. However, the backing from high-profile figures such as former U.S. President Donald Trump has contributed to increased public awareness and the launch of numerous clinical trials aimed at evaluating its efficacy.

These clinical trials were conducted by the Lancet team, dividing participants into control and treatment groups. Preliminary results from these trials did not show promising outcomes that justified the drug's widespread use. In fact, the death rate was higher, and most patients who died did so due to cardiac arrhythmia. This condition, where heartbeats become irregular, has further exacerbated the health deterioration in COVID-19 infected patients. Consequently, the World Health Organization (WHO) decided to suspend further trials of hydroxychloroquine in treating coronavirus.

Taking Hydroxychloroquine Preemptively is Not Advised

Taking hydroxychloroquine preemptively to prevent COVID-19 is not a recommended strategy. This drug should only be considered for use in selected patients under medical supervision. The drug can cause serious side effects, including critical heart rhythm problems and other adverse reactions.

The Food and Drug Administration (FDA) and WHO have updated their stance, revoking the emergency use authorization for hydroxychloroquine and chloroquine in treating COVID-19. Recent clinical trials in hospitalized patients have shown that these medications provided no benefit in reducing the likelihood of death or accelerating recovery.

Emerging Research and Scientific Data

The Lancet study specifically examined the use of the two medications in hospitalized patients with COVID-19. The findings indicated that both drugs can produce severe side effects, particularly cardiac arrhythmia. This condition poses a significant risk to the health of critically ill patients. It is crucial for healthcare providers to weigh these risks against potential benefits before administering these drugs to patients.

Understanding the safety concerns associated with hydroxychloroquine is vital for ensuring informed and safe medical practices. Patients should consult their healthcare providers for personalized advice and not rely on unverified information. Staying updated with the latest scientific findings will help in making informed decisions regarding the use of this drug.